<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064077</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0204</org_study_id>
    <secondary_id>NCI-2012-02540</secondary_id>
    <secondary_id>CDR0000306463</secondary_id>
    <secondary_id>GOG-0204</secondary_id>
    <secondary_id>GOG-0204</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00064077</nct_id>
  </id_info>
  <brief_title>Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix</brief_title>
  <official_title>A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying four combination chemotherapy regimens using
      cisplatin to compare how well they work in treating women with stage IVB, recurrent, or
      persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel,
      vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing
      so they stop growing or die. It is not yet known which combination chemotherapy regimen
      containing cisplatin is most effective in treating cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the survival and response of patients with stage IVB, recurrent, or persistent
      carcinoma of the cervix when treated with paclitaxel and cisplatin vs vinorelbine and
      cisplatin vs gemcitabine and cisplatin vs topotecan and cisplatin.

      II. Compare the toxic effects of these regimens in these patients. III. Compare the quality
      of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 4 treatment
      arms.

      ARM I: Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours
      on day 2.

      ARM II: Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV
      over 1-4 hours on day 1.

      ARM III: Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as
      in arm II.

      ARM IV: Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.

      In all arms, treatment repeats every 21 days for 6 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline, before courses 2 and 5, and at 9 months after study
      entry.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale</measure>
    <time_frame>3 weeks after course 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale</measure>
    <time_frame>12 weeks after course 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale</measure>
    <time_frame>9 months post-randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of response</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, assessed by Brief Pain Inventory</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, assessed by Brief Pain Inventory</measure>
    <time_frame>3 weeks after course 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, assessed by Brief Pain Inventory</measure>
    <time_frame>12 weeks after course 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, assessed by Brief Pain Inventory</measure>
    <time_frame>9 months post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">513</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Adenosquamous Carcinoma</condition>
  <condition>Cervical Squamous Cell Carcinoma</condition>
  <condition>Recurrent Cervical Carcinoma</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (paclitaxel, cisplatin)</arm_group_label>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, cisplatin)</arm_group_label>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm IV (topotecan, cisplatin)</arm_group_label>
    <other_name>Hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>Topotecan HCl</other_name>
    <other_name>topotecan hydrochloride (oral)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine Tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (vinorelbine, cisplatin)</arm_group_label>
    <other_name>Biovelbin</other_name>
    <other_name>Eunades</other_name>
    <other_name>KW-2307</other_name>
    <other_name>Navelbine</other_name>
    <other_name>Navelbine Ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>Vinorelbine Ditartrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or
             adenocarcinoma of the cervix

               -  Stage IVB, recurrent, or persistent disease

          -  Not amenable to curative surgery and/or radiotherapy

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by palpation, plain x-ray, CT scan, or MRI OR at least 10 mm by
                  spiral CT scan

               -  Biopsy confirmation required if lesion is less than 30 mm

               -  Target lesion must be outside of a previously irradiated field

          -  No craniospinal metastases

          -  Performance status - GOG 0-1

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times normal

          -  Alkaline phosphatase no greater than 3 times normal

          -  AST no greater than 3 times normal

          -  Creatinine ≤ 1.2 mg/dL

          -  Creatinine &gt; 1.2 mg/dL but &lt; 1.5 mg/dL AND creatinine clearance ≥ 50 mL/min

          -  No bilateral hydronephrosis not alleviated by ureteral stents or percutaneous drainage

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No prior or concurrent malignancy within the past 5 years except nonmelanoma skin
             cancer

          -  No prior malignancy whose treatment contraindicates the current study therapy

          -  No concurrent clinically significant infection

          -  No concurrent cytokines

          -  At least 6 weeks since prior chemoradiotherapy and recovered

          -  No prior chemotherapy (except when concurrently administered with radiotherapy)

          -  At least 3 weeks since prior radiotherapy and recovered

          -  Recovered from prior surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Monk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

